newsfilter
← Latest News
GlobeNewswire·

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for